TY  - JOUR
AU  - Mısır, Sema
AU  - Yaman, Serap Özer
AU  - Petrović, Nina
AU  - Sumer, Ceren
AU  - Hepokur, Ceylan
AU  - Aliyazicioglu, Yüksel
PY  - 2022
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10630
AB  - Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for BC treatment. One of the significant challenges during the treatment of BC represents resistance to chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment. Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a large group of non-coding RNAs that covalently form closed circular loops by joining their 5′, and 3′; ends. Accumulating evidence suggests that circRNAs have a vital role in cancer development, progression, and BC resistance to chemotherapy. The purpose of this review is to discuss the biological properties of circRNAs, and how circRNAs induce resistance to conventional therapeutic anti-cancer drugs used in BC treatment, by emphasizing and summarizing the potential roles of circRNAs in mechanisms of drug resistance, such as drug efflux, apoptosis dysfunction, autophagy, and DNA damage repair. CircRNAs are associated with drug resistance via ATP-binding cassette (ABC) efflux transporters, while some others by inhibition of cell apoptosis, thus leading to resistance to tamoxifen in BC cells. In contrast, others are involved in the promotion of BC cells chemoresistance by doxorubicin-induced autophagy. CircRNAs may have clinical significance in regulating or overcoming BC drug resistance and may give directions towards a novel approach to personalized BC treatment. CircRNAs may significantly contribute to the identification of new therapeutic targets for the prevention of BC chemoresistance. © 2022, Tech Science Press. All rights reserved.
T2  - Oncology Research
T1  - circRNAs in drug resistance of breast cancer
VL  - 30
IS  - 4
SP  - 157
EP  - 172
DO  - 10.32604/or.2022.027547
ER  - 

@article{
author = "Mısır, Sema and Yaman, Serap Özer and Petrović, Nina and Sumer, Ceren and Hepokur, Ceylan and Aliyazicioglu, Yüksel",
year = "2022",
abstract = "Breast cancer (BC) is the most common heterogeneous disease in women and one of the leading causes of cancer-related death. Surgery, chemotherapy, radiotherapy, hormone, and targeted therapy are the gold standards for BC treatment. One of the significant challenges during the treatment of BC represents resistance to chemotherapeutics, resistance that severely limits the use and effectiveness of the drugs used for BC treatment. Therefore, it is essential to develop new strategies to improve therapeutic efficacy. Circular RNAs (circRNAs) are a large group of non-coding RNAs that covalently form closed circular loops by joining their 5′, and 3′; ends. Accumulating evidence suggests that circRNAs have a vital role in cancer development, progression, and BC resistance to chemotherapy. The purpose of this review is to discuss the biological properties of circRNAs, and how circRNAs induce resistance to conventional therapeutic anti-cancer drugs used in BC treatment, by emphasizing and summarizing the potential roles of circRNAs in mechanisms of drug resistance, such as drug efflux, apoptosis dysfunction, autophagy, and DNA damage repair. CircRNAs are associated with drug resistance via ATP-binding cassette (ABC) efflux transporters, while some others by inhibition of cell apoptosis, thus leading to resistance to tamoxifen in BC cells. In contrast, others are involved in the promotion of BC cells chemoresistance by doxorubicin-induced autophagy. CircRNAs may have clinical significance in regulating or overcoming BC drug resistance and may give directions towards a novel approach to personalized BC treatment. CircRNAs may significantly contribute to the identification of new therapeutic targets for the prevention of BC chemoresistance. © 2022, Tech Science Press. All rights reserved.",
journal = "Oncology Research",
title = "circRNAs in drug resistance of breast cancer",
volume = "30",
number = "4",
pages = "157-172",
doi = "10.32604/or.2022.027547"
}

Mısır, S., Yaman, S. Ö., Petrović, N., Sumer, C., Hepokur, C.,& Aliyazicioglu, Y.. (2022). circRNAs in drug resistance of breast cancer. in Oncology Research, 30(4), 157-172.
https://doi.org/10.32604/or.2022.027547

Mısır S, Yaman SÖ, Petrović N, Sumer C, Hepokur C, Aliyazicioglu Y. circRNAs in drug resistance of breast cancer. in Oncology Research. 2022;30(4):157-172.
doi:10.32604/or.2022.027547 .

Mısır, Sema, Yaman, Serap Özer, Petrović, Nina, Sumer, Ceren, Hepokur, Ceylan, Aliyazicioglu, Yüksel, "circRNAs in drug resistance of breast cancer" in Oncology Research, 30, no. 4 (2022):157-172,
https://doi.org/10.32604/or.2022.027547 . .